您当前位置：首页 > 国际期刊-JOURNAL OF CHEMOTHERAPY期刊投稿发表详细信息

JOURNAL OF CHEMOTHERAPY Q3

期刊收录：
SCIE
Scopus

基本信息

期刊ISSN：
1120-009X
期刊简拼：
J CHEMOTHERAPY
年发文章数：
69
E-ISSN：
1973-9478
Gold OA文章占比
4.91%
研究文章占比：
81.16%
是否OA：
No
Jcr分区：
Q3
中科院分区：
4区

出版信息

出版商：
Maney Publishing
涉及研究方向：
医学-药学
出版国家：
ITALY
出版语言：
English
出版周期：
Bimonthly
出版年份：
1989

2023-2024最新影响因子:1.9
自引率:0.00%
五年影响因子:2
JCI期刊引文指标:0.5
h-index:45
CiteScore:3.70

期刊关键词

3区 SCIE Scopus 医学 4区 INFECTIOUS DISEASES 传染病学 ONCOLOGY 肿瘤学 PHARMACOLOGY & PHARMACY 药学

期刊简介

The Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research on all aspects of antimicrobial and antitumor chemotherapy.

The Journal publishes original experimental and clinical research articles, state-of-the-art reviews, brief communications and letters on all aspects of chemotherapy, providing coverage of the pathogenesis, diagnosis, treatment, and control of infection, as well as the use of anticancer and immunomodulating drugs.

Specific areas of focus include, but are not limited to:

· Antibacterial, antiviral, antifungal, antiparasitic, and antiprotozoal agents;

· Anticancer classical and targeted chemotherapeutic agents, biological agents, hormonal drugs, immunomodulatory drugs, cell therapy and gene therapy;

· Pharmacokinetic and pharmacodynamic properties of antimicrobial and anticancer agents;

· The efficacy, safety and toxicology profiles of antimicrobial and anticancer drugs;

· Drug interactions in single or combined applications;

· Drug resistance to antimicrobial and anticancer drugs;

· Research and development of novel antimicrobial and anticancer drugs, including preclinical, translational and clinical research;

· Biomarkers of sensitivity and/or resistance for antimicrobial and anticancer drugs;

· Pharmacogenetics and pharmacogenomics;

· Precision medicine in infectious disease therapy and in cancer therapy;

· Pharmacoeconomics of antimicrobial and anticancer therapies and the implications to patients, health services, and the pharmaceutical industry.